General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Half-Life (Normalesrd) Hours
45-55/Unchanged
Plasma Protein Binding %
>99
Volume Of Distribution L/Kg
0.12-0.15
Dose For Normal Renal Function
20 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [B]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs. 1984; 28: 292-323. [PMID: 6386426] / Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994; 26: 107-20. [PMID: 8162655]